# Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

> **NCT03801525** · PHASE2,PHASE3 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 277 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Umbralisib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03801525
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-16
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 277 (ACTUAL)
- **Why stopped:** Strategic/Business decision
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801525, "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03801525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*